Physician profile
Peter Johnson
NPI 1710148176
$4,116.06
in general payments reported to CMS, 2019-2025
24 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.44 · 2020: $235 · 2021: $176 · 2022: $420 · 2023: $477 · 2024: $1,337 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,262.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.93 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $729.50 | 2023-2025 | Caplyta |
| Tris Pharma INC | $364.53 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $336.80 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $270.08 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $140.97 | 2023-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $138.77 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $120.81 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.63 | 2023-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $94.57 | 2020-2024 | Austedo Xr, Austedo |
| Romark Laboratories, Lc | $93.68 | 2020 | |
| Axsome Therapeutics, INC. | $86.12 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $69.36 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $42.07 | 2022-2023 | Spravato |
| Ironshore Pharmaceuticals INC. | $38.97 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $35.87 | 2021 | |
| Allergan, INC. | $35.81 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.03 | 2025 | Cobenfy |
| Aquestive Therapeutics, INC. | $22.44 | 2019 | |
| Corium, LLC | $21.88 | 2025 | Azstarys |
| Catalyst Pharmaceuticals, INC. | $17.51 | 2025 | |
| Vanda Pharmaceuticals INC. | $16.44 | 2022 | |
| Bausch Health US, LLC | $12.91 | 2022 | |
| Neos Therapeutics, Lp | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.